Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study

L’uso di stent con sirolimus e’ significativamente associate alla riduzione della mortalita’ totale e della morbidita’ cardiovascolare sia a 6 mesi che a 12 mesi post-PTCA.

Andamento nel tempo dell’approccio alla coronarografia diagnostica in relazione ai progressi della PTCA

Coronarografia diagnostica e conseguenti scelte terapeutiche dopo l’avvento degli stent alla rapamicina: approccio attuale ed evoluzione degli ultimi dieci anni.

Clinical predictors of adverse events in a 1 year follow-up study post-PCI

La simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura: effetti delle statine “beyond-cholesterol”

Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.

Use of stents with sirolimus is significantly associated with a reduction in mortality and cardiovascular morbidity at 6- and 12-months post-PTCA

Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events post-PTCA: a 1 year follow-up study

La simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura: effetti delle statine “beyond-cholesterol”

Risultati del follow-up di 6 mesi in 100 pazienti con stent medicato con rapamicina rispetto ad altri 100 con stent tradizionale

Coronarografia diagnostica: evoluzione temporale in relazione ai progressi della PTCA

Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.

Triglycerides (TGs) are vehicled by multiple particles with different abilities to promote atherosclerosis. Among plasma TG-rich lipoproteins (TRLs), subspecies may or may not contain apolipoprotein E (apoE) molecules: in this study, we evaluated the relative contribution of apoE-rich and apoE-poor TRLs to coronary atherosclerosis. We selected a group of males with premature coronary artery disease (CAD) without any of the classical nonlipid risk factors and/or high plasma lipid levels and evaluated the plasma concentration of TRL subspecies in comparison with healthy controls. Patients with CAD and controls had total cholesterol and TG levels within the normal range (despite slightly, even…

Relazione tra il size delle LDL e l’estensione della malattia vasale coronarica in 72 pazienti maschi sottoposti a coronarografia diagnostica

Accumulation of ApoE-containing triglyceride-rich lipoproteins in normolipidemic men with premature coronary artery disease

Il diabete, la familiarita’ per malattie cardiovascolari e l’estensione della malattia vasale quali predittori degli eventi clinici ad 1 anno di follow-up post-PTCA

Uso degli stent medicati con rapamicina in pazienti con situazioni anatomiche o cliniche che favoriscono la restenosi: risultati del follow-up di 6 mesi su primi 100 pazienti

Dati del follow-up di 6 mesi sui primi 100 pazienti con stent medicati con rapamicina, con situazioni anatomiche e cliniche favorenti la restenosi

Dati di mortalita’ e morbilita’ del follow-up condotto su 123 pazienti sottoposti ad angioplastica coronarica

Clinical predictors of adverse events in a 1 year follow-up study post-PTCA.

Correlazione in 309 pazienti coronaropatici tra i livelli di HDL-colesterolo e l’estensione della coronaropatia

Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease

Accumulo di VLDL/IDL contenenti ApoE in maschi normolipemici con cardiopatia ischemica precoce

Simvastatin reduces the levels of ApoE-containing triglyceride-rich lipoproteins in men with premature coronary artery disease

Accumulation of remnant-like particles in normolipidemic men with premature coronary artery disease

USE OF THE DRUG ELUTING STENTS WITH RAPAMICIN IN PATIENTS WITH ANATOMICAL OR CLINICAL PATTERNS FAVOURING RESTENOSIS: RESULTS OF A 6-MONTHS FOLLOW-UP ON THE FIRST 100 PATIENS.

Drug eluting stents's use in patients with anatomical or clinical patterns favouring restenosis: a 6-months follow-up study

Risultati immediati e a lungo termine della valvuloplastica mitralica percutanea: un’esperienza di dieci anni.

Effetti “beyond-cholesterol” delle statine: la terapia con simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura

Valutazione dell’outcome a distanza post-PTCA: risultati del follow-up ad un anno